the overall 42 % cr rate from hidac/asnase v 12 % from hidac in patients with refractory aml indicates that hidac/asnase is not cross-resistant with standard-dose cytarabine ( sdac ) and anthracyclines .
C0278793
hidac/asnase
C0003993
asnase